Shares of ESSA Pharma Inc. (NASDAQ:EPIX - Get Free Report) TSE: EPI passed above its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $1.72 and traded as high as $1.76. ESSA Pharma shares last traded at $1.72, with a volume of 59,875 shares traded.
Analysts Set New Price Targets
Several research analysts recently commented on EPIX shares. Piper Sandler cut shares of ESSA Pharma from an "overweight" rating to a "neutral" rating and reduced their target price for the stock from $15.00 to $2.00 in a report on Monday, November 4th. Jefferies Financial Group downgraded shares of ESSA Pharma from a "buy" rating to a "hold" rating in a research note on Monday, November 4th. Finally, Oppenheimer downgraded ESSA Pharma from an "outperform" rating to a "market perform" rating in a research report on Monday, November 4th.
View Our Latest Analysis on EPIX
ESSA Pharma Stock Performance
The firm has a fifty day moving average price of $1.72 and a 200 day moving average price of $3.48. The company has a market cap of $76.35 million, a price-to-earnings ratio of -2.49 and a beta of 1.60.
ESSA Pharma (NASDAQ:EPIX - Get Free Report) TSE: EPI last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.01). On average, analysts expect that ESSA Pharma Inc. will post -0.42 EPS for the current fiscal year.
Hedge Funds Weigh In On ESSA Pharma
Hedge funds and other institutional investors have recently bought and sold shares of the business. GTS Securities LLC acquired a new stake in shares of ESSA Pharma in the fourth quarter valued at approximately $30,000. Squarepoint Ops LLC acquired a new stake in ESSA Pharma during the 4th quarter valued at $26,000. Two Sigma Advisers LP acquired a new stake in ESSA Pharma during the 4th quarter valued at $148,000. Two Sigma Investments LP acquired a new position in shares of ESSA Pharma in the fourth quarter valued at $378,000. Finally, Tang Capital Management LLC acquired a new position in shares of ESSA Pharma in the fourth quarter valued at $7,697,000. Institutional investors own 75.12% of the company's stock.
ESSA Pharma Company Profile
(
Get Free Report)
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.
Featured Articles
Before you consider ESSA Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ESSA Pharma wasn't on the list.
While ESSA Pharma currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
